RepliCel Life Sciences Announces Re-pricing of Warrants
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 03/06/17 -- RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB: REPCD)(TSX VENTURE: RP)(FRANKFURT: P6P2), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announces that it has applied to the TSX Venture Exchange (the "Exchange") for an amendment to the exercise price of 148,226 non-transferable share purchase warrants (the "April Warrants") expiring April 10, 2017 from $5.00 to $1.14 and 173,900 non-transferable share purchase warrants (the "November Warrants") expiring on November 20, 2017 from $4.00 to $1.14. All other terms of the April Warrants and the November Warrants will remain the same. The amendment to the exercise price is subject to the approval of the Exchange.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The Company's product pipeline is comprised of two ongoing clinical trials (RCT-01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair restoration product under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles. The Company has also developed a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications. Please visit for additional information.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Lee Buckler
CEO and President
604-248-8693
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.03.2017 - 00:08 Uhr
Sprache: Deutsch
News-ID 528471
Anzahl Zeichen: 0
contact information:
Town:
VANCOUVER, BRITISH COLUMBIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 359 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"RepliCel Life Sciences Announces Re-pricing of Warrants"
steht unter der journalistisch-redaktionellen Verantwortung von
RepliCel Life Sciences Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
